VectorY Therapeutics, a biotech company developing vectorized antibody therapies for the treatment of neurodegenerative diseases, has appointed Jim Scibetta as Chief Executive Officer.
 
Former CEO and founder, Sander van Deventer will become President of R&D and will continue to drive the development of VectorY’s pipeline, including its lead program, VTx-002, a novel vectorized antibody targeting TDP-43 for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is currently in IND-enabling studies.

About Jim Scibetta

Jim Scibetta brings more than 20 years of executive leadership experience, having built earlier stage companies focused on developing novel therapeutics for high unmet medical needs into mature biotechnology companies. Scibetta will also join VectorY’s Board of Directors.
 
“I am delighted to join VectorY at such a pivotal time,” said Scibetta. “VectorY has impressive early data behind its technology and preclinical programs, and the Company is supported by a leading investor syndicate. There is a clear path to achieving clinical data for its lead asset, VTx-002, with considerable future potential from the pipeline emanating from the novel VectorY platform.”
 
He added: “VTx-002 was designed by Sander and his team based on a deep understanding of both the underlying pathological drivers of this devastating disease and the advancements in science and therapeutic modalities specifically needed to attack those unique disease drivers. I look forward to working with and building on the talented team at VectorY to continue the advancement of this new treatment.”
 
Scibetta has served on numerous private and public company boards at biotech companies, including CEO of Maverick Therapeutics leading to its 2021 acquisition by Takeda, President of Pacira BioSciences during its growth from a clinical stage private company to a commercial stage public company worth more than $2 billion, and CFO of BioEnvision, having been instrumental in its sale to Genzyme. He recently served as a senior consultant to Rock Springs Capital, and has also served on the Boards and in executive positions at Matinas BioPharma, ImmuneID, and Aquestive Therapeutics.
 
Prior to his biotech company-building career, Scibetta spent 13 years in healthcare investment banking at Shattuck Hammond Partners and Paine Webber. He has an MBA from the University of Michigan.